In the Xiamen Trade Fair on 8th Sep. 2021, Xiamen Biotime Biotechnology Co., Ltd. released new drugs development strategy, planning to invest more than 1 billion yuan of scientific research funds in the medical and health field in the next three years, and at the same time set up another 1 billion yuan to focus on investment Funds mainly in the medical and health field.

Xiamen Biotime Biotechnology surpassed the IVD boundary and entered the field of new drugs, which attracted the attention of the industry, and quickly reached extensive strategic cooperation with Hangzhou Adlai Nortye Biopharma Co., Ltd. and Shanghai Medicilon Inc.

Less than a year, in the beginning of autumn in 2022, Biotime Pharmaceutical (Shanghai) Co., Ltd. was officially put into operation on August 8.

At the unveiling ceremony, Yu Jianping, Deputy General Manager, delivered a speech instead of Chief Executive Zhang Guofeng.

From Biotime to Biotime Pharmaceutical, from diagnosis to treatment, we have made a big leap. Today we are here to witness an important historical moment of Biotime Pharmaceutical. I believe that with everyone's support, Biotime Pharmaceutical will get a better tomorrow.

Afterwards, Lin Baode, head of R&D of Biotime Pharmaceutical, delivered a speech.

Today, Biotime Pharmaceutical may be a little spark, but we believe that it will definitely ignite and attract the attention of the industry in the future!

Biotime Pharmaceutical Shanghai R&D Center is located on Cailun Road, Zhangjiang High-tech Park, which is known as China Pharmaceutical Valley.

The research center that covers an area of about 700 square meters has invested nearly 50 million yuan to configure various high-end precision instruments and equipment, and built a modern laboratory.